Atrial fibrillation (AF) – frequent cause of stroke, dementia and heart failure – affects 2-3 % of the population in Europe and the USA. We are increasing our understanding of the causes of the condition, but prevention and therapies are not harnessing mechanistic insights. This means that, apart from the use of anticoagulation to prevent AF related strokes, treatment is still not having a great impact on outcomes.